

CorNotes

CVI SEMINAR SERIES

The next CVI Seminar will be held on **October 23, 2008** at **4:00 p.m.** in **Building 120, Room 150**. Our speaker is:

Gregory Morley, Ph.D.
Assistant Professor of Medicine
NYU School of Medicine
New York, NY

The title of Dr. Morley's talk is:

"Optical Mapping in the Investigation of Myocardial Physiology"

For further information about the CVI Seminar Series, please contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

October 9..... Dr. Jody Martin

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm. 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

October 23.....Dr. Kyle Henderson

The title of Dr. Henderson's talk is:

Aging and Thyroid Dysfunction=Diastolic Heart Failure: Is the Equation Reversible?

For more information about this seminar series, contact Dr. Samarel at x72821.

TRIFECTA CLINICAL TRIAL

Dr. Mamdouh Bakhos, Chairman of the Department of Thoracic and Cardiovascular Surgery, is the principal investigator conducting an observational, prospective evaluation of the Trifecta valve on behalf of St. Jude Medical.

This observational cohort study will assess the clinical safety and effectiveness of aortic valve replacement (using the Trifecta valve) by prospectively recording adverse event rates, clinical status as indicated by New York Heart Association (NYHA) functional classification, hemodynamic performance, and hematology analysis.

To be entered into the study, the patient must: 1) require aortic valve replacement, 2) be 18 years of age or older, 3) give written informed consent for participation prior to surgery, and 4) be willing to undergo all study procedures and return for follow-up. A patient will be excluded if they: 1) are pregnant or nursing, 2) have a prosthetic valve in the tricuspid, mitral or pulmonic site, 3) have active endocarditis, 4) have had an acute neurological event within 30 days prior to surgery, 5) are on renal dialysis, 6) have a history of substance abuse in the previous year, 7) are currently a prison inmate, 8) are currently enrolled in an investigational drug or device study, 9) has significant other cardiovascular abnormality such as a dissection, or 10) has a life expectancy less than two years.

For more information or to alert the CV Surgery team of potential participants, please contact the project's coordinator, Sally Botkin at 708-327-2494.

